Director/PDMR Shareholding
EDX Medical Group plc announced that Chief Executive Officer Dr. Michael Hudson purchased 28,526 ordinary shares at an average price of 10.57 pence, increasing his holding to 20,600,000 shares, and a closely associated person, Sebastian Hudson, bought 22,500 shares at an average of 10.03 pence, bringing his total to 50,000 shares. Following these transactions, Dr. Hudson controls 20,650,000 ordinary shares, representing 5.34% of the company's issued share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your EDX notes
CAMBRIDGE, UK: EDX Medical Group plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, announces that it was informed yesterday that Dr Michael Hudson, Chief Executive Officer of the Company, purchased a total of 28,526 ordinary shares in the Company on 22 December 2025, at an average price per share of 10.57 pence. Dr Hudson now holds 20,600,000 ordinary shares in the Company.
The Company was also informed yesterday that Sebastian Hudson, a person closely associated with Dr Michael Hudson, purchased 22,500 shares on 22 December 2025, at an average price per share of 10.03 pence. Mr Hudson now holds 50,000 ordinary shares in the Company.
Taken together, Dr Hudson controls 20,650,000 ordinary shares, representing 5.34% of the Company's issued share capital.
The directors of the Company accept responsibility for the contents of this announcement.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Dr Michael Hudson |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR / Chief Executive Officer |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | EDX Medical Group PLC |
| b) | LEI | 213800BZVJZTMCZ6DJ63 |
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each |
| Identification code | ISIN: GB00BNDMJS47 | |
| b) | Nature of the transaction | Purchase of shares |
| c) | Price(s) and volume(s) | |
| Price | Volume | |
| £0.1075 | 13,624 | |
| £0.1040 | 14,902 | |
| d) | Aggregated information | |
| - Aggregated volume | 28,526 | |
| - Price | £0.1057 | |
| e) | Date of the transaction | 2025-12-22 |
| f) | Place of the transaction | AQSG - Aquis Growth Market (Equity) |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Sebastian Hudson |
| 2 | Reason for the notification | |
| a) | Position/status | Person Closely Associated with Dr Michael Hudson |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | EDX Medical Group PLC |
| b) | LEI | 213800BZVJZTMCZ6DJ63 |
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each |
| Identification code | ISIN: GB00BNDMJS47 | |
| b) | Nature of the transaction | Purchase of shares |
| c) | Price(s) and volume(s) | |
| Price | Volume | |
| £0.1020 | 7,425 | |
| £0.0995 | 15,075 | |
| d) | Aggregated information | |
| - Aggregated volume | 22,500 | |
| - Price | £0.1003 | |
| e) | Date of the transaction | 2025-12-22 |
| f) | Place of the transaction | AQSG - Aquis Growth Market (Equity) |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.